Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 9/2013

01-09-2013 | Original Article

Antiemetic prophylaxis and frequency of chemotherapy-induced nausea and vomiting in palliative first-line treatment of colorectal cancer patients: the Northern Bavarian IVOPAK I Project

Authors: Sonja Koch, Axel Wein, Jürgen Siebler, Frank Boxberger, Markus F. Neurath, Hanns-Detlev Harich, Werner Hohenberger, Frank Dörje

Published in: Supportive Care in Cancer | Issue 9/2013

Login to get access

Abstract

Purpose

This study aims to evaluate adherence to guidelines of antiemetic prophylaxis and frequency of chemotherapy-induced nausea and vomiting (CINV) in the palliative first-line treatment of colorectal cancer (CRC) patients in Northern Bavaria.

Methods

We collected detailed information on chemotherapy and supportive drugs in 103 patients within a prospective observational study. The study was conducted to determine quality of care within an interdisciplinary context (first endpoint) and direct costs of palliative treatment for patients with CRC between 2006 and 2010 (second endpoint, Emmert et al. (Eur J Health Econ, 2012) [1]). In this paper, we evaluate adherence to Multinational Association of Supportive Care in Cancer (MASCC) 2006 recommendations for prophylaxis of CINV during the first administration of chemotherapy as well as incidence and grade of CINV within 120 h thereafter.

Results

Of the patients studied, 95 patients (92 %) received moderately emetogenic (oxaliplatin- and/or irinotecan-containing combined chemotherapy treatment) and eight (8 %) received low emetogenic chemotherapy (either 5-fluorouracil (5-FU) or capecitabine monotherapy). Antiemetic prophylaxis could be assessed in 101 out of 103 (98 %) of patients. MASCC-recommended antiemetic prophylaxis was prescribed in three patients (3 %). Nonadherence was mainly caused by omission of dexamethasone. Nausea and/or vomiting occurred in 18 patients (18 %) within a 120-h period. All documented episodes were grade 1 or 2 according to the Common Toxicity Criteria of the National Cancer Institute. None of these patients received the recommended prophylaxis for CINV. In only one patient, antiemetic prophylaxis was intensified during the next chemotherapy application.

Conclusions

In the Integrated Health Care in the Palliative Treatment of Colorectal Carcinoma (IVOPAK) I Project, adherence to the MASCC clinical recommendations was very poor. Extent of CINV in this patient population seems to be underestimated. There is an urgent need to improve clinicians' awareness of this patient-relevant side effect.
Literature
1.
2.
Statistisches Bundesamt (2012) Gesundheit: Todesursachen in Deutschland 2010, Fachserie 12 Reihe 4. Wiesbaden
3.
Schmiegel W, Pox C, Reinacher-Schick A et al (2010) S3 guidelines for colorectal carcinoma: results of an evidence-based consensus conference on February 6/7, 2004 and June 8/9, 2007 (for the topics IV, VI and VII). Z Gastroenterol 48(1):65–136CrossRef
4.
Basch E, Prestrud AA, Hesketh PJ et al (2011) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 29(31):4189–4198CrossRef
5.
Roila F, Herrstedt J, Aapro M et al (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21(Suppl 5):v232–v243CrossRef
6.
Kaiser R (2005) Antiemetic guidelines: are they being used? Lancet Oncol 6(8):622–625CrossRef
7.
Griffin AM, Butow PN, Coates AS et al (1996) On the receiving end. V: patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol 7(2):189–195CrossRef
8.
Roila F, Hesketh PJ, Herrstedt J (2006) Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 17(1):20–28PubMed
9.
DCTD N, NIH, DHHS (1999) Cancer Therapy Evaluation Program Common Toxicity Criteria, version 2.0.
10.
Burmeister H, Aebi S, Studer C et al (2012) Adherence to ESMO clinical recommendations for prophylaxis of chemotherapy-induced nausea and vomiting. Support Care Cancer 20(1):141–147CrossRef
11.
Drug Utilization Review Team in Oncology (2003) Antiemetic prescription in Italian breast cancer patients submitted to adjuvant chemotherapy. Support Care Cancer 11(12):785–789CrossRef
12.
Fabi A, Barduagni M, Lauro S et al (2003) Is delayed chemotherapy-induced emesis well managed in oncological clinical practice? An observational study. Support Care Cancer 11(3):156–161PubMed
13.
The Italian Group for Antiemetic Research (1998) Transferability to clinical practice of the results of controlled clinical trials: the case of antiemetic prophylactic treatment for cancer chemotherapy-induced nausea and vomiting. Ann Oncol 9(7):759–765CrossRef
14.
Brugnatelli S, Gattoni E, Grasso D et al (2011) Single-dose palonosetron and dexamethasone in preventing nausea and vomiting induced by moderately emetogenic chemotherapy in breast and colorectal cancer patients. Tumori 97(3):362–366CrossRef
15.
Abbrederis K, Lorenzen S, Rothling N et al (2009) Chemotherapy-induced nausea and vomiting in the treatment of gastrointestinal tumors and secondary prophylaxis with aprepitant. Onkologie 32(1–2):30–34PubMed
16.
Cabana MD, Rand CS, Powe NR et al (1999) Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA 282(15):1458–1465CrossRef
17.
Grunberg S (2012) Patient-centered management of chemotherapy-induced nausea and vomiting. Cancer Control 19(2 Suppl):10–15CrossRef
18.
Bero LA, Grilli R, Grimshaw JM et al (1998) Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings. The Cochrane Effective Practice and Organization of Care Review Group. BMJ 317(7156):465–468CrossRef
19.
Dranitsaris G, Leung P, Warr D (2001) Implementing evidence based antiemetic guidelines in the oncology setting: results of a 4-month prospective intervention study. Support Care Cancer 9(8):611–618CrossRef
20.
Mertens WC, Higby DJ, Brown D et al (2003) Improving the care of patients with regard to chemotherapy-induced nausea and emesis: the effect of feedback to clinicians on adherence to antiemetic prescribing guidelines. J Clin Oncol 21(7):1373–1378CrossRef
21.
Majek O, Gondos A, Jansen L et al (2012) Survival from colorectal cancer in Germany in the early 21st century. Br J Cancer 106(11):1875–1880CrossRef
22.
Grunberg S (2012) Improving control of chemotherapy-induced nausea and vomiting. Cancer Control 19(2 Suppl):2CrossRef
23.
Molassiotis A, Coventry PA, Stricker CT et al (2007) Validation and psychometric assessment of a short clinical scale to measure chemotherapy-induced nausea and vomiting: the MASCC antiemesis tool. J Pain Symptom Manage 34(2):148–159CrossRef
Metadata
Title
Antiemetic prophylaxis and frequency of chemotherapy-induced nausea and vomiting in palliative first-line treatment of colorectal cancer patients: the Northern Bavarian IVOPAK I Project
Authors
Sonja Koch
Axel Wein
Jürgen Siebler
Frank Boxberger
Markus F. Neurath
Hanns-Detlev Harich
Werner Hohenberger
Frank Dörje
Publication date
01-09-2013
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 9/2013
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-013-1801-z

Other articles of this Issue 9/2013

Supportive Care in Cancer 9/2013 Go to the issue

Review Article

Nurse-led follow-up care for cancer patients: what is known and what is needed

Review Article

A systematic review of health-related quality of life instruments in patients with cancer cachexia

Original Article

Does gender influence outcomes from a multidisciplinary intervention for quality of life designed for patients with advanced cancer?

Original Article

Factors associated with depressive symptoms in cancer family caregivers of patients receiving chemotherapy

Original Article

A survey of Canadian cancer patients’ perspectives on the characteristics and treatment of breakthrough pain

Original Article

How much does it cost to care for survivors of colorectal cancer? Caregiver’s time, travel and out-of-pocket costs
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits